The Agony of the Agonists: a Review of Impulsivity and Withdrawal Syndromes in Parkinson's Disease Treatment

References

• Fahn S , PoeweW. Levodopa: 50 years of a revolutionary drug for parkinson disease. Mov. Disord.30(1), 1–3 (2015).
   PubMed Web of Science ®Google Scholar
• Nyholm D , StepienV. Levodopa fractionation in Parkinson's disease. J. Parkinsons Dis.4(1), 89–96 (2014).
   PubMedGoogle Scholar
• Goetz CG , PalG. Initial management of Parkinson's disease. BMJ349, g6258 (2014).
   PubMedGoogle Scholar
• Fahn S , OakesD, ShoulsonIet al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med.351(24), 2498–2508 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson Study G . Pramipexole vs levodopa as initial treatment for parkinson disease: A randomized controlled trial. Parkinson study group. JAMA284(15), 1931–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Rascol O , BrooksDJ, KorczynAD, De DeynPP, ClarkeCE, LangAE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med.342(20), 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Antonini A , PoeweW. Fibrotic heart-valve reactions to dopamine-agonist treatment in parkinson's disease. Lancet Neurol.6(9), 826–829 (2007).
   PubMed Web of Science ®Google Scholar
• Morrish P . Prescribing in Parkinson's disease: a story of hope and adverse events. Pract. Neurol.12(5), 335–340 (2012).
   PubMedGoogle Scholar
• PD MED Collaborative Group . Long-term effectiveness of dopamine agonists and monoamine oxidase b inhibitors compared with levodopa as initial treatment for Parkinson's disease (pd med): a large, open-label, pragmatic randomised trial. Lancet384(9949), 1196–1205 (2014).
   PubMed Web of Science ®Google Scholar
• Driver-Dunckley E , SamantaJ, StacyM. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology61(3), 422–423 (2003).
   PubMed Web of Science ®Google Scholar
• Weintraub D , KoesterJ, PotenzaMNet al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol.67(5), 589–595 (2010).
   PubMed Web of Science ®Google Scholar
• Callesen MB , Scheel-KrugerJ, KringelbachML, MollerA. A systematic review of impulse control disorders in Parkinson's disease. J. Parkinsons Dis.3(2), 105–138 (2013).
   PubMedGoogle Scholar
• Voon V , HassanK, ZurowskiMet al. Prospective prevalence of pathologic gambling and medication association in parkinson disease. Neurology66(11), 1750–1752 (2006).
   PubMed Web of Science ®Google Scholar
• Isaias IU , SiriC, CiliaR, De GaspariD, PezzoliG, AntoniniA. The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov. Disord.23(3), 411–415 (2008).
   PubMed Web of Science ®Google Scholar
• Antonini A , SiriC, SantangeloGet al. Impulsivity and compulsivity in drug-naive patients with parkinson's disease. Mov. Disord.26(3), 464–468 (2011).
   PubMed Web of Science ®Google Scholar
• Blum K , SheridanPJ WR, BravermanER, ChenTJ, ComingsDE. Dopamine d2 receptor gene variants: association and linkage studies in impulsive–adddivtive–compulsive behavior. Pharmacogenetics5(3), 121–141 (1995).
   PubMedGoogle Scholar
• Hoenicka J , Garcia-RuizPJ, PonceGet al. The addiction-related gene ANKK1 in parkinsonian patients with impulse control disorder. Neurotox. Res.27(3), 205–208 (2015).
   PubMed Web of Science ®Google Scholar
• Fantini ML , MacedoL, ZibettiMet al. Increased risk of impulse control symptoms in Parkinson's disease with REM sleep behavior disorder. J. Neurol. Neurosurg. Psychiatry86(2), 174–179 (2015).
   PubMed Web of Science ®Google Scholar
• Bayard S , DauvilliersY, YuHet al. Impulse control disorder and rapid eye movement sleep behavior disorder in Parkinson's disease. Parkinsonism Relat. Disord.20(12), 1411–1414 (2014).
   PubMed Web of Science ®Google Scholar
• Volkmann J , DanielsC, WittK. Neuropsychiatric effects of subthalamic neurostimulation in parkinson disease. Nat. Rev. Neurol.6(9), 487–498 (2010).
   PubMed Web of Science ®Google Scholar
• Biundo R , WeisL, FacchiniSet al. Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. Mov. Disord.30(5), 688–695 (2015).
   PubMed Web of Science ®Google Scholar
• Leroi I , AndrewsM, McdonaldKet al. Apathy and impulse control disorders in Parkinson's disease: a direct comparison. Parkinsonism Relat. Disord.18(2), 198–203 (2012).
   PubMed Web of Science ®Google Scholar
• Vriend C , PattijT, Van Der WerfYDet al. Depression and impulse control disorders in parkinson's disease: two sides of the same coin? Neurosci. Biobehav. Rev. 38, 60–71 (2014).
   PubMed Web of Science ®Google Scholar
• Edwards MJ . Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine ‘switch’. J. Neurol. Neurosurg. Psychiatry84(2), 120 (2013).
   PubMed Web of Science ®Google Scholar
• Bancos I , NannengaMR, BostwickJM, SilberMH, EricksonD, NippoldtTB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case–control study. Clin. Endocrinol. (Oxf.)80(6), 863–868 (2014).
   PubMed Web of Science ®Google Scholar
• Cornelius JR , Tippmann-PeikertM, SlocumbNL, FrerichsCF, SilberMH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep33(1), 81–87 (2010).
   PubMed Web of Science ®Google Scholar
• Rizos A , Martinez-MartinP, MartinAet al. European multicentre srudy of tolerability and impulse control disordersn with short and extended release dopamine agonists in real life PD. Mov. Dis.28(Suppl. 1), S215–S216 (2013).
   Google Scholar
• Garcia-Ruiz PJ , Martinez CastrilloJC, Alonso-CanovasAet al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J. Neurol. Neurosurg. Psychiatry85(8), 840–844 (2014).
   PubMed Web of Science ®Google Scholar
• Schreglmann SR , GantenbeinAR, EiseleG, BaumannCR. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat. Disord.18(2), 207–209 (2012).
   PubMed Web of Science ®Google Scholar
• Smith N , KitchenhamN, Bowden-JonesH. Pathological gambling and the treatment of psychosis with aripiprazole: case reports. Br. J. Psychiatry199(2), 158–159 (2011).
   PubMed Web of Science ®Google Scholar
• Moore TJ , GlenmullenJ, MattisonDR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern. Med.174(12), 1930–1933 (2014).
   PubMed Web of Science ®Google Scholar
• Wingo TS , EvattM, ScottB, FreemanA, StacyM. Impulse control disorders arising in 3 patients treated with rotigotine. Clin. Neuropharmacol.32(2), 59–62 (2009).
   PubMed Web of Science ®Google Scholar
• Weintraub D , HoopsS, SheaJAet al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov. Disord.24(10), 1461–1467 (2009).
   PubMed Web of Science ®Google Scholar
• Weintraub D , DavidAS, EvansAH, GrantJE, StacyM. Clinical spectrum of impulse control disorders in parkinson's disease. Mov. Disord.30(2), 121–127 (2015).
   PubMed Web of Science ®Google Scholar
• Macphee GJ , ChaudhuriKR, DavidAS, WorthP, WoodB. Managing impulse control behaviors in Parkinson's disease: practical guidelines. Br. J. Hosp. Med. (Lond.)74(3), 160–166 (2013).
   PubMed Web of Science ®Google Scholar
• Collins GT , WoodsJH. Narrowing in on compulsions: dopamine receptor functions. Exp. Clin. Psychopharmacol.16(6), 498–502 (2008).
   PubMed Web of Science ®Google Scholar
• Blum K , ChenAL, GiordanoJet al. The addictive brain: all roads lead to dopamine. J. Psychoactive Drugs44(2), 134–143 (2012).
   PubMed Web of Science ®Google Scholar
• Volkow ND , WangGJ, TelangFet al. Cocaine cues and dopamine in dorsal striatum: Mechanism of craving in cocaine addiction. J. Neurosci.26(24), 6583–6588 (2006).
   PubMed Web of Science ®Google Scholar
• Evans AH , PaveseN, LawrenceADet al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann. Neurol.59(5), 852–858 (2006).
   PubMed Web of Science ®Google Scholar
• O'sullivan SS , WuK, PolitisMet al. Cue-induced striatal dopamine release in parkinson's disease-associated impulsive-compulsive behaviors. Brain134(Pt 4), 969–978 (2011).
   PubMedGoogle Scholar
• Rabinak CA , NirenbergMJ. Dopamine agonist withdrawal syndrome in parkinson disease. Arch. Neurol.67(1), 58–63 (2010).
   PubMedGoogle Scholar
• Pondal M , MarrasC, MiyasakiJet al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J. Neurol. Neurosurg. Psychiatry84(2), 130–135 (2013).
   PubMed Web of Science ®Google Scholar
• Schlesinger I , ErikhI, ZaaroorM. Dopamine agonist withdrawal syndrome: The apomorphine solution. Arch Neurol67(9), 1155; author reply 1156 (2010).
   PubMedGoogle Scholar
• Halbig TD , TseW, FrisinaPGet al. Subthalamic deep brain stimulation and impulse control in parkinson's disease. Eur. J. Neurol.16(4), 493–497 (2009).
   PubMed Web of Science ®Google Scholar
• Bach JP , OertelWH, DodelR, JessenF. Treatment of hypersexuality in parkinson's disease with carbamazepine – a case report. Mov. Disord.24(8), 1241–1242 (2009).
   PubMed Web of Science ®Google Scholar
• Thomas A , BonanniL, GambiF, Di IorioA, OnofrjM. Pathological gambling in parkinson disease is reduced by amantadine. Ann. Neurol.68(3), 400–404 (2010).
   PubMed Web of Science ®Google Scholar
• Bermejo PE , Ruiz-HueteC, AncionesB. Zonisamide in managing impulse control disorders in Parkinson's disease. J. Neurol.257(10), 1682–1685 (2010).
   PubMed Web of Science ®Google Scholar
• Rotondo A , BoscoD, PlastinoM, ConsoliA, BoscoF. Clozapine for medication-related pathological gambling in parkinson disease. Mov. Disord.25(12), 1994–1995 (2010).
   PubMed Web of Science ®Google Scholar
• Lyons KE , FriedmanJH, HermanowiczNet al. Orally disintegrating selegiline in parkinson patients with dopamine agonist-related adverse effects. Clin. Neuropharmacol.33(1), 5–10 (2010).
   PubMed Web of Science ®Google Scholar
• Seeman P . Parkinson's disease treatment may cause impulse-control disorder via dopamine d3 receptors. Synapse69(4), 183–189 (2015).
   PubMed Web of Science ®Google Scholar
• Gerschlager W , BloemBR. Managing pathological gambling in parkinson's disease with enteral levodopa/carbidopa infusions. Mov. Disord.24(12), 1858–1860 (2009).
   PubMed Web of Science ®Google Scholar
• Demetriades P , RickardsH, CavannaAE. Impulse control disorders following deep brain stimulation of the subthalamic nucleus in Parkinson's disease: clinical aspects. Parkinsons Dis.2011, 658415 (2011).
   PubMed Web of Science ®Google Scholar
• Nirenberg MJ . Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson's disease surgery. Brain133(11), e155; author reply e156 (2010).
   PubMedGoogle Scholar
• Bandini F , PrimaveraA, PizzornoM, CocitoL. Using stn dbs and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat. Disord.13(6), 369–371 (2007).
   PubMed Web of Science ®Google Scholar
• Ardouin C , VoonV, WorbeYet al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov. Disord.21(11), 1941–1946 (2006).
   PubMed Web of Science ®Google Scholar
• Witjas T , BaunezC, HenryJMet al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov. Disord.20(8), 1052–1055 (2005).
   PubMed Web of Science ®Google Scholar
• Shotbolt P , MoriartyJ, CostelloAet al. Relationships between deep brain stimulation and impulse control disorders in Parkinson's disease, with a literature review. Parkinsonism Relat. Disord.18(1), 10–16 (2012).
   PubMed Web of Science ®Google Scholar
• Lhommee E , KlingerH, ThoboisSet al. Subthalamic stimulation in parkinson's disease: Restoring the balance of motivated behaviors. Brain135(Pt 5), 1463–1477 (2012).
   PubMed Web of Science ®Google Scholar
• Castrioto A , FunkiewiezA, DebuBet al. Iowa gambling task impairment in Parkinson's disease can be normalised by reduction of dopaminergic medication after subthalamic stimulation. J. Neurol. Neurosurg. Psychiatry86(2), 186–190 (2015).
   PubMed Web of Science ®Google Scholar
• Grover ND , LimayeRP, GokhaleDV, PatilTR. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease. Indian J. Pharmacol.45(6), 547–555 (2013).
   PubMed Web of Science ®Google Scholar
• Broadstock M , BallardC, CorbettA. Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease. Expert Rev. Clin. Pharmacol.7(6), 779–786 (2014).
   PubMed Web of Science ®Google Scholar
• Cummings J , IsaacsonS, MillsRet al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled Phase 3 trial. Lancet383(9916), 533–540 (2014).
   PubMed Web of Science ®Google Scholar
• Tanwani P , FernieBA, NikcevicAV, SpadaMM. A systematic review of treatments for impulse control disorders and related behaviors in Parkinson's disease. Psychiatry Res.225(3), 402–406 (2015).
   PubMed Web of Science ®Google Scholar
• Papay K , XieSX, SternMet al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology83(9), 826–833 (2014).
   PubMed Web of Science ®Google Scholar
• Tsai SY , PokrassMJ, KlauerNR, De CredicoNE, SuTP. Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders. Expert Opin. Ther. Targets18(12), 1461–1476 (2014).
   PubMed Web of Science ®Google Scholar
• Lammel S , LimBK, MalenkaRC. Reward and aversion in a heterogeneous midbrain dopamine system. Neuropharmacology76(Pt B), 351–359 (2014).
   PubMedGoogle Scholar
• Raja M , BentivoglioAR. Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson's disease and other disorders. Curr. Drug Saf.7(1), 63–75 (2012).
   PubMedGoogle Scholar
• Okai D , Askey-JonesS, SamuelM, DavidAS, BrownRG. Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson's disease. Mov. Disord.30(5), 736–739 (2015).
   PubMed Web of Science ®Google Scholar
• Parkinson's disease: diagnosis and management in primary and secondary care. Department of Health (2006). http://publications.nice.org.uk/parkinsons-disease-cg35.
   Google Scholar
• SIGN guidelines diagnosis and pharmacological management of Parkinson's disease. www.sign.ac.uk/guidelines/fulltext/113.
   Google Scholar
• Parkinson's UK Impulsive and Compulsive Behaviour Monitoring tool. www.parkinsons.org.uk/content/impulsive-and-compulsive-behavior-parkinsons-monitoring-tool.
   Google Scholar
• National Parkinsons Foundation: The importance of a monitoring strategy when prescribing dopamine agonists. www.parkinson.org/Patients/Patients---On-The-Blog/November-2014/The-Importance-of-a-Monitoring-Strategy-When-Presc.aspx.
   Google Scholar